Status:
UNKNOWN
The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors
Lead Sponsor:
University of Athens
Conditions:
Bullous Pemphigoid
Eligibility:
All Genders
18+ years
Brief Summary
The investigators conducted a prospective study which included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 201...
Detailed Description
Bullous pemphigoid (BP) is the most common chronic autoimmune skin disease which is characterized by the presentation of subepidermical blisters and mostly affects elderly patients . Recent studies ha...
Eligibility Criteria
Inclusion
- biopsy proven bullous pemphigoid
- severe bullous pemphigoid
- recent manifestation of bullous pemphigoid (last four months)
Exclusion
- non bullous pemphigoid
- presentation of bullous pemphigoid more than four months
- treatment with DPP4is more than two years
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT04469582
Start Date
April 1 2009
End Date
December 31 2020
Last Update
September 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Attikon" University General Hospital
Athens, Attica, Greece, 12462